Kimball Electronics (KE) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
1 Feb, 2026Executive summary
Q4 net sales were $430.2 million, down 13% year-over-year, with declines across all verticals and regions; FY24 net sales reached $1.715 billion, the second highest in company history.
Divested the Automation, Test, and Measurement (AT&M) business on July 31, 2024, to sharpen strategic focus and improve liquidity.
Inventory reduced by $112 million (25%) year-over-year, supporting positive free cash flow and improved balance sheet.
Operating environment remained challenging, with broad-based end-market demand weakness and cost containment efforts.
Financial highlights
Q4 gross margin was 8.5%, down 150 basis points year-over-year due to lower absorption and weaker AT&M performance.
Adjusted operating income for Q4 was $20.9 million (4.9% of sales), down from $31.5 million (6.3%) last year; FY24 adjusted operating income was $74.3 million (4.3% margin).
Adjusted net income for Q4 was $8.4 million ($0.33 per diluted share), compared to $19 million ($0.76) last year.
Cash and equivalents at quarter-end were $78 million; operating cash flow for Q4 was $48.5 million.
Borrowings on credit facility were $294.8 million at quarter-end, with $142.1 million in available credit.
Outlook and guidance
Fiscal 2025 net sales expected between $1.44 billion and $1.54 billion, an 8%-14% decrease from 2024, excluding AT&M.
Adjusted operating income margin guidance is 4%-4.5% of net sales, with Q1 expected below the full-year range.
Capital expenditures projected at $40-$50 million, split between growth and maintenance.
Revenue mix and segment trends from Q4 expected to continue into Q1; medical declines to moderate as FDA recall impact anniversaries.
Guidance methodology for adjusted operating income will exclude stock compensation expense starting FY25.
Latest events from Kimball Electronics
- Raised FY26 guidance and expanded medical focus drive profitable growth outlook.KE
Company presentation20 Mar 2026 - Medical segment growth and facility expansion drive strategic shift and margin improvement.KE
2026 KeyBanc Capital Markets Healthcare Forum19 Mar 2026 - Q2 sales fell 5% but margins and 2026 guidance improved on strong medical growth.KE
Q2 20265 Feb 2026 - Streamlined operations and global focus drive resilience despite EMS market headwinds.KE
The Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - FY 2025 sales expected to decline 8–14% as focus shifts to automation, medical, and debt reduction.KE
2024 Annual Gateway Conference22 Jan 2026 - Q1 sales fell 15% as restructuring, divestitures, and strong cash flow drove debt reduction.KE
Q1 202516 Jan 2026 - Strategic medical CMO expansion and operational discipline set the stage for future growth.KE
The Gateway Conference 20255 Jan 2026 - Q2 FY25 net sales fell 15% year-over-year, but liquidity and balance sheet improved.KE
Q2 202523 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and ESG progress amid strong governance.KE
Proxy Filing1 Dec 2025